Doctors prescribe Exparel (bupivacaine liposome injectable suspension) for pain relief after surgery. The drug’s cost may depend on your dosage and whether you have health insurance. It may also ...

Exparel (bupivacaine liposomal) is a brand-name injection that’s prescribed after surgery for pain relief or as a nerve block in adults and some children. The cost of the drug, with and without ...

According to the American College of Surgeons, 15 million Americans undergo surgery each year. Despite this high frequency and the significant impact these procedures can have on patients, no ...

Exparel (bupivacaine liposome) is a prescription drug used to help reduce pain after surgery. Exparel can cause side effects that range from mild to serious. Examples include nausea and constipation.

Exparel (bupivacaine liposomal) is a brand-name drug prescribed for pain relief after surgery in adults and some children. Exparel comes as an injection that’s given as a single dose by a healthcare ...

FDA expands indications for bupivacaine liposome injectable suspension (Exparel; Pacira BioSciences, Inc.) for use in adult patients as an adductor canal block and a sciatic nerve block in the ...

Pacira BioSciences, Inc. PCRX announced that the phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statistically ...

Pacira BioSciences, Inc. PCRX announced that the FDA has approved its supplemental new drug application (sNDA) for its marketed product, Exparel, to address a new indication. The latest nod from the ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...

PARSIPPANY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results from ...

Pacira BioSciences, Inc. PCRX has announced positive top-line data from a phase III study evaluating its marketed drug, Exparel, as a single-dose femoral nerve block in the adductor canal for ...